Halozyme Therapeutics Inc. Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B), while Schwab US Large Cap Growth ETF trades at $36.72 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 5.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Schwab US Large Cap Growth ETF is more actively traded (8,554,399 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| HALO | SCHG | |
|---|---|---|
Market Cap | $12.58B | $65.01B |
Volume | 2,179,278 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $36.93 |
52-Week Low | $61.63 | $28.10 |
Typical Hold Time | 1 Days | 50 Days |
Enterprise Value | $14.49B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →